DISC MEDICINE INC (IRON)
Health Care · Biotechnology · NASDAQ
Disc Medicine is a clinical-stage biopharmaceutical firm advancing a pipeline of novel therapies to treat serious hematologic and red blood cell disorders by targeting heme biosynthesis and iron homeostasis.
What DISC MEDICINE INC does
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic diseases. Its pipeline targets heme biosynthesis and iron homeostasis, with a primary focus on treating erythropoietic porphyrias (EPP and XLP) and various forms of anemia. The company utilizes validated molecular mechanisms to develop novel treatments for red blood cell disorders.
Themes: hematology, porphyria treatment, anemia therapy, red blood cell disorders, heme biosynthesis pathway, iron homeostasis
Fundamentals
- Price$76.00 as of 2026-10-21 close
- Market cap$2.9B as of 2026-07-23 (share count; price 2026-10-21)
- 1-year return-11.8% 2025-10-21 close $86.17 → 2026-10-21 close $76.00
- P/En/a negative earnings
- ROE-28.7% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equity0.09 borrowings, leases excluded / equity — 10-Q/10-K balance sheet 2026-06-30
- Beta1.16 as of 2026-09-02
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How IRON compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$65M | -$60M | -$1.54 | -$44M† | $0† |
| Q1 FY2026 2026-03-31 | -$70M | -$64M | -$1.65 | -$62M | $0 |
| Q4 FY2025 2025-12-31 | -$67M† | -$61M† | -$1.62† | -$43M† | $20000† |
| Q3 FY2025 2025-09-30 | -$68M | -$62M | -$1.77 | -$48M† | $26000† |
| Q2 FY2025 2025-06-30 | -$61M | -$55M | -$1.58 | -$48M† | $36000† |
| Q1 FY2025 2025-03-31 | -$40M | -$34M | -$1.02 | -$41M | $851000 |
| Q4 FY2024 2024-12-31 | -$35M† | -$29M† | -$0.98† | -$28M† | $449000† |
| Q3 FY2024 2024-09-30 | -$33M | -$27M | -$0.89 | -$17M† | -$8000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$99M
- Short-term investments$619M
- Total debt$59M borrowings only; leases excluded
- Net debt-$658M total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How DISC MEDICINE INC looks technically
DISC MEDICINE INC (IRON) is trading 7.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 45 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 2 trading days ago. It is 23.6% below its highest point of the past year. Trading volume is running unusually high — about 4.8× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 7.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +7.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $71.46 | $71.46 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $70.91 | $70.91 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 45 trading days ago — a "golden cross", a bullish long-term signal | 45 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 7.2% above | +7.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 45, with buyers in control | 45.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($55.00 to $81.50) — its "stochastic" reading is 79 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 79.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $99.50 | $99.50 |
|---|---|---|
| From the 52-week high | it is 23.6% below its 52-week high (its highest price of the past year) | -23.6% |
| Above the 52-week low | it is 90.0% above its 52-week low (its lowest price of the past year) | +90.0% |
| Below the 52-week high | it is 23.6% below its highest point of the past year | 23.6% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $572.55 (set on 2021-03-15) | $572.55 |
| Given back of the 52-week move | over the past year its closes ranged ($55.74 to $94.11), and it has recovered around half of its fall from last year’s high — 53% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $79.45 to $80.68. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 52.8% |
| From the all-time high | it is 86.7% below its all-time high | -86.7% |
| Nearest price level | it is trading 5.1% above a support level at $72.12 — a price it turned at five times since 2025-12-19, most recently on 2026-07-28. Since 2024-10-21 it has 12 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.1% |
| All-time low | its lowest closing price on record is $15.00 (set on 2022-12-30) | $15.00 |
| Above the all-time low | it is 406.7% above its all-time low | +406.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.50 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.50 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $50.96 and $77.61 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $50.96 – $64.29 – $77.61 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.9% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges above its 200-day average price (7.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 4.8× its 30-day average, a sign of heightened interest | 4.83× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 7 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 7 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-21 2.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -2.1% |
|---|---|---|
| Open gap | it gapped 27.9% above the previous close 2 sessions ago and has not traded back through the level it left behind at 56.84 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +27.9% |
| Gap filled | a 2.1% gap down opened on 2026-10-21 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 11.0 percentage points (the stock gained 11.0% while the market lost 0.1%) | +11.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 2.8 percentage points (the stock gained 0.6% while the market gained 3.3%) | -2.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 0.2 percentage points (the stock gained 10.0% while the market gained 9.8%) | +0.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 27.0 percentage points (the stock lost 11.8% while the market gained 15.2%) | -27.0% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.9% of the share price, which is taken to mean a barrier that gives way easily. | +1.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $70.37 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | +8.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $73.06 — a volume-weighted average of daily closes over 59 sessions, not a true tick-by-tick VWAP. | +4.0% |
Price levels it has turned at before
IRON last closed at $76.00 on 2026-10-21. Since 2024-10-21 it has turned at 12 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $72.12 | Support | 5.1% below the last close | turned there five times · 2025-12-19 to 2026-07-28 |
| $82.31 | Resistance | 8.3% above the last close | turned there five times · 2025-11-11 to 2026-08-12 |
| $68.76 | Support | 9.5% below the last close | turned there five times · 2024-11-11 to 2026-02-25 |
| $83.78 | Resistance | 10.2% above the last close | turned there twice · 2026-02-05 to 2026-08-26 |
| $64.93 | Support | 14.6% below the last close | turned there four times · 2025-08-18 to 2026-06-08 |
| $90.09 | Resistance | 18.5% above the last close | turned there twice · 2025-10-28 to 2025-11-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Unusually heavy trading volume · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$103.17 range $83.00 – $128.00; median $100.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IRON
- Consensus EPS estimate-$1.71 next reporting period, as of 2026-10-16
- Estimate change, 30 days+$0.02778 from -$1.74, on 2026-09-11, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure, particularly the Phase 3 APOLLO trial, poses a significant risk to the company's future.","The company has received a complete response letter (CRL) from the FDA for its lead candidate, creating regulatory uncertainty for approval.","Significant reliance on a limited number of product candidates for future revenue potential."]
What changed in the latest 10-Q
AI-assisted comparison of IRON's 10-Q filed 2026-07-30 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-30) states interim data from HELIOS was also presented in June 2026 in addition to June 2025.
- Newer filing (2026-07-30) states that in the Type A meeting during the second quarter of 2026, the FDA indicated that results of the ongoing Phase 3 APOLLO trial, if successful, could serve as the basis for a response to the CRL and could potentially support a traditional approval.
- Newer filing (2026-07-30) states that the company plans to submit a response to the CRL if APOLLO is successful.
- Newer filing (2026-07-30) names DISC-0974 as selcodebart and uses the name selcodebart throughout the iron homeostasis section.
- Newer filing (2026-07-30) states interim data in June 2026 for RALLY-MF demonstrated meaningful overall anemia responses.
- Newer filing (2026-07-30) states the company initiated RALLY-IBD, a Phase 2 clinical trial of selcodebart in patients with IBD and anemia, in the first quarter of 2026, with initial data anticipated in 2027.
- Newer filing (2026-07-30) states the company is planning exploratory studies in additional patient populations with anemia of chronic disease.
- Removed:
- Older filing (2026-05-05) states that in the end-of-Phase 2 meeting in September 2024, the FDA agreed with the potential for reduction of PPIX to serve as a surrogate endpoint to support a potential accelerated approval of bitopertin in EPP and XLP.
- Older filing (2026-05-05) states that in the Type C meeting in December 2024, the company aligned with the FDA on the design of APOLLO and that in the setting of an accelerated approval APOLLO would serve as a post-marketing confirmatory trial.
- Older filing (2026-05-05) states that in October 2025 the company was awarded a Commissioner's National Priority Voucher (CNPV) from the FDA for bitopertin in EPP and XLP, including details about the CNPV program announced in June 2025.
- Older filing (2026-05-05) states that the FDA agreed that clinical data from AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers whole blood metal-free PPIX.
- Older filing (2026-05-05) states that the company had scheduled a Type A meeting with the FDA during the second quarter of 2026 to review the approach for potentially resubmitting the NDA.
- Older filing (2026-05-05) uses the name DISC-0974 rather than selcodebart in the iron homeostasis section.
- Reworded:
- Newer filing (2026-07-30) refers to DISC-0974 as selcodebart with no mention of the prior DISC-0974 designation in the names, while older filing (2026-05-05) refers to it as DISC-0974.
- Newer filing (2026-07-30) describes the FDA's Type A meeting outcome as indicating APOLLO results, if successful, could serve as the basis for a response to the CRL and potentially support traditional approval; older filing (2026-05-05) described the Type A meeting as being scheduled for the second quarter of 2026.
- Newer filing (2026-07-30) states the company plans to submit a response to the CRL if APOLLO is successful; older filing (2026-05-05) stated the company planned to submit a response to the CRL following topline data in the fourth quarter of 2026.
- Newer filing (2026-07-30) phrases the CRL conclusion as resulting in uncertainty regarding whether bitopertin's effect on PPIX is reasonably likely to predict clinical benefit, while older filing (2026-05-05) includes the additional phrase that the FDA agreed bitopertin significantly lowers whole blood metal-free PPIX.
- Newer filing (2026-07-30) states an end-of-Phase 2 meeting with the FDA for selcodebart in anemia of MF is expected by the end of 2026 if RALLY-MF data are positive; older filing (2026-05-05) did not explicitly include this expectation in the provided text.
- The newer filing text is truncated at the end of the DISC-3405 sentence.
- Notes:
- The newer filing text appears truncated mid-sentence at the end ("DISC-3405, a monoclonal antibod"), so later sections of the MD&A could not be compared.
- The older filing text also appears truncated mid-sentence at the end ("If po"), so later sections of the MD&A could not be compared.
Risk Factors
- Added:
- In the newer filing (filed 2026-07-30), the net losses figure is stated as $123.0 million for the six months ended June 30, 2026.
- In the newer filing (filed 2026-07-30), the accumulated deficit is stated as $633.2 million as of June 30, 2026.
- Removed:
- In the older filing (filed 2026-05-05), the net losses figure was stated as $63.5 million for the three months ended March 31, 2026.
- In the older filing (filed 2026-05-05), the accumulated deficit was stated as $573.7 million as of March 31, 2026.
- In the older filing (filed 2026-05-05), the phrase 'complete, our ongoing and planned clinical trials' included a comma after 'complete'; the newer filing (filed 2026-07-30) removed the comma, reading 'complete our ongoing and planned clinical trials'.
- Reworded:
- The newer filing (filed 2026-07-30) changed the reporting period for net losses from 'for the three months ended March 31, 2026 and 2025' to 'for the six months ended June 30, 2026 and 2025'.
- The newer filing (filed 2026-07-30) changed the net loss figure from $63.5 million (three months ended March 31, 2026) to $123.0 million (six months ended June 30, 2026), and the comparative 2025 figure from $34.1 million to $89.3 million.
- The newer filing (filed 2026-07-30) changed the accumulated deficit reference from 'as of March 31, 2026' to 'as of June 30, 2026'.
- Notes:
- The provided texts are excerpts of the Risk Factors section, not the complete section; changes occurring beyond the excerpt would not be captured.
- Both source texts are truncated mid-sentence at the same point in the 'successfully address the prevalence, duration and severity...' bullet, so any changes after that point could not be assessed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 32 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 30 days · read to 2026-10-170 buys · 9 sells ($3M) — 1 selling insider
- Last 90 days · read to 2026-10-170 buys · 32 sells ($14M) — 4 selling insiders
- Last 180 days · read to 2026-10-170 buys · 48 sells ($21M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-21. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IRON's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding IRON as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,495,824
- Reported value $694,524,565
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IRON's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IRON had 7,270,420 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
IRON had 18.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.79 days to cover at the same settlement.
- Reported short interest (shares) 7,270,420
- Short interest (% of shares outstanding) 18.9%
- Prior settlement (shares) 7,207,702
- Reported change 0.87%
- Days to cover (reported) 12.79
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Alnylam Pharmaceuticals (ALNY)
- Ironwood Pharmaceuticals (IRWD)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- GlaxoSmithKline (GSK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IRON vs…
IRON ranks in…
Frequently asked questions
What does DISC MEDICINE INC (IRON) do?
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing therapies for serious hematologic diseases. Its pipeline targets heme biosynthesis and iron homeostasis, with a primary focus on treating erythropoietic porphyrias (EPP and XLP) and various forms of anemia. The company utilizes validated molecular mechanisms to develop novel treatments for red blood cell disorders.
What sector is DISC MEDICINE INC (IRON) in?
DISC MEDICINE INC (IRON) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are DISC MEDICINE INC's (IRON) competitors?
Notable peers of DISC MEDICINE INC (IRON) include Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, Amgen, Bristol Myers Squibb and GlaxoSmithKline. This peer set is informational only — not financial advice.
Is DISC MEDICINE INC (IRON) overbought or oversold right now?
DISC MEDICINE INC (IRON) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IRON come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.